SABS Financial Statements

Balance sheet, income statement, cash flow, and dividends for Sab Biotherapeutics Inc (SABS).


$35.02M Market Cap.

As of 03/31/2025 5:00 PM ET (MRY) • Disclaimer

SABS Market Cap. (MRY)


SABS Shares Outstanding (MRY)


SABS Assets (MRY)


Total Assets

$44.20M

Total Liabilities

$18.23M

Total Investments

$11.86M

SABS Income (MRY)


Revenue

$1.32M

Net Income

-$34.11M

Operating Expense

$44.23M

SABS Cash Flow (MRY)


CF Operations

-$34.29M

CF Investing

-$11.96M

CF Financing

-$1.17M

SABS Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

0%

0%

0%

-

2020

$0

-

-

0%

-

SABS Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$44,195,469 (-47.35%)

$83,941,253 (64.90%)

$50,904,927 (-37.26%)

$81,140,931 (43.52%)

Assets Current

$23,792,229 (-59.61%)

$58,906,863 (166.58%)

$22,097,453 (-55.97%)

$50,191,950 (45.67%)

Assets Non-Current

$20,403,240 (-18.50%)

$25,034,390 (-13.10%)

$28,807,474 (-6.92%)

$30,948,981 (40.15%)

Goodwill & Intangible Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

$25,969,576 (-54.68%)

$57,299,441 (84.49%)

$31,058,142 (-19.43%)

$38,549,913 (-1.17%)

Property Plant & Equipment Net

$19,921,138 (-19.30%)

$24,684,160 (-12.90%)

$28,339,780 (-8.43%)

$30,948,981 (40.15%)

Cash & Equivalents

$8,897,966 (-84.27%)

$56,566,066 (275.93%)

$15,046,894 (-61.95%)

$39,545,018 (213.59%)

Accumulated Other Comprehensive Income

-$135,410 (-612.53%)

$26,420 (0%)

$0 (0%)

$0 (0%)

Deferred Revenue

$0 (0%)

$1,322,410 (0%)

$0 (0%)

$100,000 (0.00%)

Total Investments

$11,862,746 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Investments Current

$11,862,746 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Investments Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Inventory

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Trade & Non-Trade Receivables

$0 (0%)

$0 (0%)

$5,556,577 (-30.64%)

$8,010,708 (-61.06%)

Trade & Non-Trade Payables

$1,694,722 (79.16%)

$945,927 (-74.29%)

$3,679,116 (-17.53%)

$4,460,892 (-39.71%)

Accumulated Retained Earnings (Deficit)

-$124,168,850 (-37.87%)

-$90,063,541 (-88.14%)

-$47,869,755 (-64.34%)

-$29,128,951 (-143.06%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Debt

$4,668,909 (-20.96%)

$5,907,059 (-0.37%)

$5,928,758 (-30.38%)

$8,515,802 (4.80%)

Debt Current

$811,842 (-56.18%)

$1,852,799 (32.70%)

$1,396,247 (-54.96%)

$3,100,187 (87.02%)

Debt Non-Current

$3,857,067 (-4.86%)

$4,054,260 (-10.55%)

$4,532,511 (-16.31%)

$5,415,615 (-16.28%)

Total Liabilities

$18,225,893 (-31.59%)

$26,641,812 (34.24%)

$19,846,785 (-53.40%)

$42,591,018 (142.96%)

Liabilities Current

$7,979,600 (-26.21%)

$10,813,317 (-27.88%)

$14,993,344 (-43.33%)

$26,455,273 (139.16%)

Liabilities Non-Current

$10,246,293 (-35.27%)

$15,828,495 (226.13%)

$4,853,441 (-69.92%)

$16,135,745 (149.46%)

SABS Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$1,322,410 (-40.94%)

$2,238,991 (-90.63%)

$23,904,181 (-60.73%)

$60,876,078 (10.21%)

Cost of Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Selling General & Administrative Expense

$13,981,263 (-41.25%)

$23,799,306 (45.27%)

$16,383,285 (-4.11%)

$17,085,692 (152.29%)

Research & Development Expense

$30,251,667 (83.18%)

$16,515,005 (-54.68%)

$36,438,513 (-36.28%)

$57,183,589 (104.90%)

Operating Expenses

$44,232,930 (9.72%)

$40,314,311 (-23.68%)

$52,821,798 (-28.88%)

$74,269,281 (114.15%)

Interest Expense

$318,401 (0.99%)

$315,284 (4.54%)

$301,584 (2.42%)

$294,459 (-37.24%)

Income Tax Expense

$0 (0%)

$0 (0%)

$25,629 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$34,105,309 (19.17%)

-$42,193,786 (-125.14%)

-$18,740,804 (-9.31%)

-$17,144,531 (-185.22%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$34,105,309 (19.17%)

-$42,193,786 (-125.14%)

-$18,740,804 (-9.31%)

-$17,144,531 (-185.22%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$34,105,309 (19.17%)

-$42,193,786 (-125.14%)

-$18,740,804 (-9.31%)

-$17,144,531 (-185.22%)

Weighted Average Shares

$9,261,918 (67.74%)

$5,521,487 (-87.31%)

$43,524,971 (59.20%)

$27,339,180 (7.67%)

Weighted Average Shares Diluted

$9,261,918 (67.74%)

$5,521,487 (-87.31%)

$43,524,971 (59.20%)

$27,339,180 (1.21%)

Earning Before Interest & Taxes (EBIT)

-$33,786,908 (19.32%)

-$41,878,502 (-127.43%)

-$18,413,591 (-9.28%)

-$16,850,072 (-181.85%)

Gross Profit

$1,322,410 (-40.94%)

$2,238,991 (-90.63%)

$23,904,181 (-60.73%)

$60,876,078 (10.21%)

Operating Income

-$42,910,520 (-12.70%)

-$38,075,320 (-31.67%)

-$28,917,617 (-115.91%)

-$13,393,203 (-165.15%)

SABS Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

-$11,962,267 (-7733.63%)

-$152,704 (92.69%)

-$2,090,024 (80.90%)

-$10,943,657 (13.98%)

Net Cash Flow from Financing

-$1,172,626 (-101.76%)

$66,773,137 (6250.81%)

$1,051,411 (-97.07%)

$35,891,419 (299.58%)

Net Cash Flow from Operations

-$34,292,009 (-36.52%)

-$25,119,405 (-7.08%)

-$23,459,511 (-1280.73%)

$1,986,873 (-80.14%)

Net Cash Flow / Change in Cash & Cash Equivalents

-$47,668,100 (-214.81%)

$41,519,172 (269.48%)

-$24,498,124 (-190.95%)

$26,934,635 (329.96%)

Net Cash Flow - Business Acquisitions and Disposals

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

-$11,625,005 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Capital Expenditure

-$337,262 (-120.86%)

-$152,704 (92.69%)

-$2,090,024 (80.90%)

-$10,943,657 (13.98%)

Issuance (Repayment) of Debt Securities

-$906,999 (-132.30%)

-$390,445 (67.05%)

-$1,185,113 (-176.73%)

$1,544,444 (268.26%)

Issuance (Purchase) of Equity Shares

$20,409 (112.99%)

$9,582 (-99.57%)

$2,236,524 (-93.49%)

$34,346,975 (246.93%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

-$241,198 (-1429.35%)

$18,144 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$2,941,796 (21.38%)

$2,423,720 (-9.37%)

$2,674,203 (15.53%)

$2,314,682 (78.68%)

Depreciation Amortization & Accretion

$4,792,595 (27.96%)

$3,745,282 (13.77%)

$3,291,878 (99.07%)

$1,653,597 (201.65%)

SABS Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

100.00% (0.00%)

100.00% (0.00%)

100.00% (0.00%)

100.00% (0.00%)

Profit Margin

-2579.00% (-36.85%)

-1884.50% (-2303.70%)

-78.40% (-178.01%)

-28.20% (-177.47%)

EBITDA Margin

-2192.50% (-28.74%)

-1703.10% (-2590.52%)

-63.30% (-153.20%)

-25.00% (-165.27%)

Return on Average Equity (ROAE)

-84.30% (41.74%)

-144.70% (-170.47%)

-53.50% (-21.04%)

-44.20% (-140.33%)

Return on Average Assets (ROAA)

-59.00% (33.41%)

-88.60% (-171.78%)

-32.60% (-30.92%)

-24.90% (-146.11%)

Return on Sales (ROS)

-2554.90% (-36.60%)

-1870.40% (-2329.09%)

-77.00% (-177.98%)

-27.70% (-174.26%)

Return on Invested Capital (ROIC)

-79.90% (58.60%)

-193.00% (-228.79%)

-58.70% (-12.67%)

-52.10% (-170.41%)

Dividend Yield

0% (0%)

0% (0%)

0% (0%)

0%

Price to Earnings Ratio (P/E)

-1.03 (-14.56%)

-0.9 (34.40%)

-1.37 (88.93%)

-12.4

Price to Sales Ratio (P/S)

26.57 (56.74%)

16.95 (1478.58%)

1.07 (-69.38%)

3.51

Price to Book Ratio (P/B)

1.35 (114.65%)

0.63 (-23.13%)

0.82 (-90.72%)

8.81

Debt to Equity Ratio (D/E)

0.7 (50.97%)

0.47 (-27.23%)

0.64 (-42.17%)

1.1 (146.10%)

Earnings Per Share (EPS)

-3.68 (51.83%)

-7.64 (-1676.74%)

-0.43 (31.75%)

-0.63 (-179.75%)

Sales Per Share (SPS)

0.14 (-64.78%)

0.41 (-26.05%)

0.55 (-75.35%)

2.23 (2.39%)

Free Cash Flow Per Share (FCFPS)

-3.74 (18.31%)

-4.58 (-679.73%)

-0.59 (-78.96%)

-0.33 (-206.54%)

Book Value Per Share (BVPS)

2.8 (-72.98%)

10.38 (1353.50%)

0.71 (-49.36%)

1.41 (-8.20%)

Tangible Assets Book Value Per Share (TABVPS)

4.77 (-68.61%)

15.2 (1199.40%)

1.17 (-60.58%)

2.97 (33.27%)

Enterprise Value Over EBIT (EV/EBIT)

-1 (0.00%)

-1 (0.00%)

-1 (95.00%)

-20

Enterprise Value Over EBITDA (EV/EBITDA)

-1.05 (-4.49%)

-1 (33.69%)

-1.51 (93.16%)

-22.09

Asset Turnover

0.02 (-51.06%)

0.05 (-88.70%)

0.42 (-52.94%)

0.88 (-40.35%)

Current Ratio

2.98 (-45.26%)

5.45 (269.61%)

1.47 (-22.30%)

1.9 (-39.10%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$34,629,271 (-37.03%)

-$25,272,109 (1.09%)

-$25,549,535 (-185.25%)

-$8,956,784 (-229.55%)

Enterprise Value (EV)

$30,366,795 (-20.50%)

$38,196,293 (67.12%)

$22,855,770 (-93.19%)

$335,608,831

Earnings Before Tax (EBT)

-$34,105,309 (19.17%)

-$42,193,786 (-125.45%)

-$18,715,175 (-9.16%)

-$17,144,531 (-185.22%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$28,994,313 (23.97%)

-$38,133,220 (-152.18%)

-$15,121,713 (0.49%)

-$15,196,475 (-171.90%)

Invested Capital

$31,986,812 (42.36%)

$22,468,929 (-16.14%)

$26,793,447 (13.26%)

$23,656,442 (-42.29%)

Working Capital

$15,812,629 (-67.12%)

$48,093,546 (576.98%)

$7,104,109 (-70.07%)

$23,736,677 (1.47%)

Tangible Asset Value

$44,195,469 (-47.35%)

$83,941,253 (64.90%)

$50,904,927 (-37.26%)

$81,140,931 (43.52%)

Market Capitalization

$35,017,711 (-2.65%)

$35,969,420 (41.70%)

$25,383,876 (-92.52%)

$339,538,024

Average Equity

$40,453,409 (38.69%)

$29,168,556 (-16.70%)

$35,015,272 (-9.71%)

$38,778,874 (111.32%)

Average Assets

$57,813,889 (21.46%)

$47,598,031 (-17.24%)

$57,509,956 (-16.46%)

$68,839,432 (84.70%)

Invested Capital Average

$42,310,058 (95.00%)

$21,697,311 (-30.78%)

$31,346,304 (-3.03%)

$32,324,172 (16.13%)

Shares

9,229,274 (76.40%)

5,231,916 (-87.84%)

43,030,885 (-1.02%)

43,474,779